International Journal of Breast Cancer / 2018 / Article / Tab 1 / Research Article
Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia Table 1 Baseline clinical characteristics of the study patients
.Demographic details Group TCH Group TCHP valueAge (yr) 68.3 ± 6.1 65.7 ± 7.1 0.69 Gender Females 22 (100%) 23 (100%) 0.95 Menopausal status at diagnosis 23 (100%) 22 (100%) 1.00 Clinical stage at diagnosis Stage I 1 (2.6) 2 (5.2) 0.99 Stage II 3 (7.8) 1 (2.6) 0.19 Stage III 01 (2.6) 02 (5.2) 0.55 Clinical nodal status Node positive 115 ± 21.9 122 ± 21.1 0.39 Node negative 80 ± 18.1 78 ± 19.8 0.91 Clinical T stage T1 3 ± 0.1 3 ± 0.1 1.00 T2 12 ± 0.3 12 ± 0.3 0.83 T3 6 ± 0.2 4 ± 0.2 0.88 T4 2 ± 0.1 1 ± 0.1 0.56 T4d 1 ± 0.1 1 ± 0.1 0.20 Pretreatment LEVF <55% 03 ± 2.1 05 ± 2.3 0.65 >55% 20 ± 5.3 17 ± 2.7 0.76 ECOG status 0 9/23 (38%) 8/22 (34%) 1.00 1 9/23 (36%) 8/22 (33%) 1.00